To corroborate the contrast-enhanced MRI findings and to gain better insights into the potential of B1R agonists for delivering chemotherapeutic agents into CNS tumors via different routes of administration, we used the validated, highly sensitive, elemental ICP-MS method. This evidence concerns the gene BDKRB1 and central nervous system neoplasm.